Sells finished dietary supplements under the Tru Niagen brand to consumers, plus Niagen ingredients to consumer-product manufacturers and compounding facilities.
10-K for FY2025, filed Mar 4, 2026Through our consumer products segment, we provide finished dietary supplement products containing our proprietary ingredients, marketed…View ↗
Through our Ingredients segment, we develop and commercialize proprietary ingredient technologies, including food-grade Niagen® and…View ↗
Manufacturers of consumer products incorporate our food-grade Niagen® into dietary supplement and food products. U.S. FDA-registered 503B…View ↗
Consumers and distributors buy finished supplements, while manufacturers and compounding facilities buy Niagen ingredients; product sales are counted when goods ship, and research services as they are performed.
10-K for FY2025, filed Mar 4, 2026Through our consumer products segment, we provide finished dietary supplement products containing our proprietary ingredients, marketed…View ↗
Through our Ingredients segment, we develop and commercialize proprietary ingredient technologies, including food-grade Niagen® and…View ↗
Manufacturers of consumer products incorporate our food-grade Niagen® into dietary supplement and food products. U.S. FDA-registered 503B…View ↗
Since 1999, we have provided research and quality-control products and services through our analytical reference standards and services…View ↗
Revenue Recognition: The Company recognizes sales and the related cost of sales when the performance obligations are satisfied. The…View ↗
10-K for FY2025, filed Mar 4, 2026
FY2025 revenue by reportable segment ↗$129.4M
10-K for FY2025, filed Mar 4, 2026
$129.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Consumer Products segment
Sold outright
10-K for FY2025, filed Mar 4, 2026 |
75%
FY2022: 83%
|
Consumer Products segment, FY2025
$97.7M Sources
|
Sold outright |
|
Ingredients segment
Sold outright
10-K for FY2025, filed Mar 4, 2026 |
22%
FY2022: 12%
|
Ingredients segment, FY2025
$28.7M Sources
|
Sold outright |
|
Analytical Reference Standards and Services segment
|
2.4%
FY2022: 4.5%
|
Analytical Reference Standards and Services segment, FY2025
$3.1M Sources
|
Consumers can buy Tru Niagen directly through the company site or online marketplaces, or from retailers and healthcare-practitioner resellers; ingredient sales go to manufacturers and compounding facilities through commercial partnerships.
10-K for FY2025, filed Mar 4, 2026In the United States, we distribute Tru Niagen® products directly to consumers through our proprietary e-commerce platform TruNiagen.com…View ↗
In Canada, we distribute Tru Niagen® products directly to consumers through our proprietary e-commerce platform. Internationally, we…View ↗
Our ingredients segment is primarily supported through strategic partnerships, as we do not currently offer our ingredient products…View ↗
Food-grade Niagen® is sold to manufacturers of consumer products, which incorporate the ingredient into dietary supplement and food…View ↗
Yes. It kept 13 cents of every revenue dollar as net income in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$1.2MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 4, 2026
For the full year 2026, the Company expects the e-commerce business to grow 10% to 15% year-over-year. We continue to expect the remainder…View ↗
8-K, filed May 6, 2026
Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference…View ↗
Growing. Revenue grew 92% in 4 years, from $67.4M in FY2021 to $129.4M in FY2025, about 18% a year.
Exit from reference standards
The older report describes an analytical standards and services business; the latest report says the company agreed to sell that segment.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 4, 2026Since 1999, we have provided research and quality-control products and services through our analytical reference standards and services…View ↗
On February 24, 2026, we entered into an agreement to sell our analytical reference standards and services segment. Following completion of…View ↗
Pharmaceutical-grade products
The latest report adds pharmaceutical-grade Niagen for compounding facilities and Niagen Plus products, alongside the older report's ingredient sales to partners.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 4, 2026Through our ingredients segment, we provide Niagen® in ingredient form to our strategic partners, including Nestec Ltd. (Nestlé), a global…View ↗
Loading...